INSM1 Biomarker Testing for LSD1 Inhibitor Patient Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic methods for intractable cancers, such as small-cell lung cancer and acute myelocytic leukemia, are inadequate, and there is a need for effective chemotherapy strategies targeting LSD1 inhibitors based on novel mechanisms.

Innovation Solution

A method for predicting the therapeutic effect of LSD1 inhibitors in cancer patients by measuring the expression level of INSM1, a transcription factor, to identify those likely to benefit from chemotherapy, using specific biphenyl compounds or LSD1 inhibitors like GSK2879552, ORY-1001, and GSK690.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If LSD1 inhibitors are used to treat intractable cancers, then therapeutic effectiveness is improved, but patient selection accuracy deteriorates without biomarker guidance

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidpatient selection accuracy

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent introduces INSM1 as an intermediary biomarker that mediates between the patient's tumor characteristics and the response to LSD1 inhibitors. By measuring INSM1 expression levels in tumor samples, the patent enables accurate patient selection for LSD1 inhibitor therapy, resolving the contradiction between improving therapeutic effectiveness and maintaining patient selection accuracy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If chemotherapy is administered to all cancer patients, then potential therapeutic benefit is improved, but healthcare costs and unnecessary treatment deteriorate

Engineering Contradiction:

Improvetherapeutic benefitVSAvoidhealthcare costs

Core Design Contradiction:

ReliabilityVSLoss of energy

Solution Approach 1:

The patent performs preliminary action by measuring INSM1 expression levels before administering LSD1 inhibitor chemotherapy. This preliminary biomarker assessment identifies patients who are likely to respond to treatment, enabling doctors to prescribe LSD1 inhibitors only to appropriate patients. This prevents unnecessary chemotherapy administration and associated healthcare costs while ensuring therapeutic benefit for responsive patients.

Inventive Principle:

Principle #10Preliminary action

3Ease of operation

If existing therapeutic methods are used for intractable cancers, then treatment simplicity is improved, but therapeutic efficacy deteriorates

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces the mechanical/system approach of empirical chemotherapy selection with a biomarker-based diagnostic system. By substituting the simple but ineffective approach of administering chemotherapy to all patients with an INSM1 expression analysis system, the patent maintains ease of operation through standardized biomarker testing while dramatically improving therapeutic efficacy for intractable cancers.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12435128B2Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1

Publication Date: 2025.10.07 TAIHO PHARMA CO LTD

AI summary

A method for predicting a therapeutic effect of a chemotherapy using an antitumor agent comprising an LSD1 inhibitor in a cancer patient based on an expression level of INSM1 in a sample containing tumor cells isolated from the cancer patient.